Literature DB >> 26683996

Puromycin aminonucleoside increases podocyte permeability by modulating ZO-1 in an oxidative stress-dependent manner.

Tae-Sun Ha1, Hye-Young Park2, Su-Bin Seong2, Hee Yul Ahn3.   

Abstract

Puromycin aminonucleoside (PAN)-induced nephrosis is a widely studied animal model of human idiopathic nephrotic syndrome because PAN injection into rats results in increased glomerular permeability with the characteristic ultrastructural changes in podocytes similar to human nephrosis. To investigate the role of zonula occludens (ZO)-1 and oxidative stress on PAN-induced podocyte phenotypical changes and hyperpermeability in vitro, we cultured rat and mouse podocytes and treated with various concentrations of PAN. PAN treatment increased oxidative stress level of podocytes significantly with the induction of Nox4. In addition, PAN changed the ultrastructure of podocytes, such as shortening and fusion of microvilli, and the separation of intercellular gaps, which were improved by anti-oxidative vitamin C and Nox4 siRNA. PAN also disrupted the intercellular linear ZO-1 staining and induced inner cytoplasmic re-localization of ZO-1 protein, resulting in increased podocyte intercellular permeability. PAN reduced ZO-1 protein amount and mRNA expression in a dose-dependent manner, which means that PAN could also modulate ZO-1 protein transcriptionally. However, the decreased ZO-1 protein of podocytes by PAN was improved by Nox4 siRNA transfection. Furthermore, vitamin C mitigated the quantitative and distributional disturbances of ZO-1 protein caused by PAN. Our results demonstrate that the phenotypical changes of intercellular ZO-1 by oxidative stress via Nox4 likely contribute to the glomerular hyperpermeability caused by PAN.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  NADPH oxidase; Nephrotic syndrome; Oxidative stress; Podocyte; Proteinuria; Puromycin aminonucleoside; ZO-1

Mesh:

Substances:

Year:  2015        PMID: 26683996     DOI: 10.1016/j.yexcr.2015.12.001

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  5 in total

1.  Montelukast improves the changes of cytoskeletal and adaptor proteins of human podocytes by interleukin-13.

Authors:  Tae-Sun Ha; Ja Ae Nam; Su-Bin Seong; Moin A Saleem; Se Jin Park; Jae Il Shin
Journal:  Inflamm Res       Date:  2017-06-12       Impact factor: 4.575

2.  GSK-3β as a target for protection against transient cerebral ischemia.

Authors:  Wei Wang; Mingchang Li; Yuefei Wang; Zhongyu Wang; Wei Zhang; Fangxia Guan; Qianxue Chen; Jian Wang
Journal:  Int J Med Sci       Date:  2017-03-11       Impact factor: 3.738

3.  Tripterygium glycoside protects against puromycin amino nucleoside‑induced podocyte injury by upregulating autophagy.

Authors:  Jianguang Gong; Juan Jin; Li Zhao; Yiqiao Li; Yiwen Li; Qiang He
Journal:  Int J Mol Med       Date:  2018-03-29       Impact factor: 4.101

4.  Tetrandrine may treat membranous glomerulopathy via P13K/Akt signaling pathway regulation: therapeutic mechanism validation using Heymann nephritis rat model.

Authors:  Jiazhen Yin; Jiazhen Lin; Jin Yu; Xia Wei; Bin Zhu; Caifeng Zhu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Puromycin aminonucleoside triggers apoptosis in podocytes by inducing endoplasmic reticulum stress.

Authors:  Seo-Yun Min; Dong-Soo Ha; Tae-Sun Ha
Journal:  Kidney Res Clin Pract       Date:  2018-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.